Engineering high avidity CTLA4Ig for therapy of rheumatic diseases

Author：

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.12, Iss.9, 2002-09, pp. : 1455-1457

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mechanisms of CTLA-4-Ig in Tolerance Induction

Current Pharmaceutical Design, Vol. 12, Iss. 2, 2006-01 ,pp. : 149-160

Bentham Science Publishers

Access to resources Recommend Favorite

CTLA4-Ig promising in rheumatoid arthritis

Inpharma, Vol. 1, Iss. 1414, 2003-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

CTLA4-Ig: a novel immunosuppressive agent

By Najafian N. Sayegh M.H.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 9, 2000-09 ,pp. : 2147-2157

Informa Healthcare

Access to resources Recommend Favorite

Inflammatory lipids as a target for therapy in the rheumatic diseases

By McMahon Maureen Brahn Ernest

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 8, 2008-08 ,pp. : 1213-1224

Informa Healthcare

Access to resources Recommend Favorite

The Evolving Therapy of Rheumatic Diseases, The Future is Now

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 2, Iss. 1, 2002-04 ,pp. : 1-11

Bentham Science Publishers

Access to resources Recommend Favorite